Consun Pharma 1681

[winston]

not vested

[b]CONSUN PHARMA (01681.HK) initiated Overweight with target $7 - MS[/b]
2014/05/07

Morgan Stanley considered that CONSUN PHARMA (01681.HK) 0.000 (0.000%) should get a higher valuation as the group is taking a leading role in the kidney medicine market which features rapid growth.

With the diversity of products, the company has relatively smaller pricing pressure; apart from the strong sales team, the management plans to keep expanding the sales channel.

Besides, such business has higher growth compared to the industry. Given the above factors, the research house initiated an Overweight rating for the stock, with target price set at $7.

Source: AAStocks Financial News

[winston]

not vested

CONSUN PHARMA (01681.HK) 2013 net profit up 12%
2014/03/23

CONSUN PHARMA (01681.HK) 0.000 (0.000%) announced that in 2013, the turnover rose 24.9% yearly to RMB572 million; net profit rose 12.2% to RMB153 million, representing EPS of 20 fen. No final dividend was declared.


Source: AAStocks Financial News

[winston]

not vested

[b]CONSUN PHARMA (01681.HK) opens up nearly 15% from listing price[/b]
2013/12/19

CONSUN PHARMA (01681.HK) 0.000 (0.000%) , on debut, opened at $5, up about 15% from the listing price of $4.36 (closing up 13.5% to $4.95 in grey market), on volume of 56 million shares, involving transaction amount of $280 million.

Source: AAStocks Financial News

[winston]

not vested

CONSUN PHARMA (01681.HK) soars on prospect of upbeat results
2014/08/06

CONSUN PHARMA (01681.HK) +0.010 (+0.173%) , after issuing a positive profit alert, registered gain today, and it was last $5.99, up 8%, on volume rising to 5.39 million shares, the highest for five months.

The Company had issued a positive profit alert, projecting substantial increase in net profit for the 6 months ended 30 June, thanks to the continuous growth of sales of the group’s kidney medicines, contrast medium and other medicines during the period, coupled with the interest income from the IPO proceeds.

Source: AAStocks Financial News

[winston]

not vested

Consider subscribing for Consun Pharmaceutical (01681.HK) with cash - Matthew Kwok
2013/12/10

Matthew Kwok, chief strategist at China Yinsheng Securities, said Consun Pharmaceutical (01681.HK) +0.010 (+0.173%) 's revenues grew at over 35% CAGR and profit at 31.4% CAGR over the past three years.

Kwok recommended investors to subscribe for Consun Pharmaceutical with cash due to its impressive performance.

Source: AAStocks Financial News